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PATHOPHYSIOLOGY OF AGE-DEPENDENT HYPERTENSION IN 
MALE SPRAGUE-DAWLEY RATS 
JERRY DU HAI 
ABSTRACT 
Background: Hypertension is a major health concern with a myriad of possible 
causes. Sodium is a major component of blood pressure regulation implicated in 
the maintenance of fluid volume. The blood pressure response to changes in salt 
intake varies considerably among individuals; salt-sensitive individuals exhibit 
increases in blood pressure parallel to elevated sodium intake, whereas salt-
resistant individuals maintain constant blood pressure regardless of variations in 
sodium intake. Salt-Sensitive Hypertension (SSH) develops due to an impairment 
of normal mechanisms that react to an elevated sodium load. Aging is another 
major risk factor for the development of hypertension. The effects of aging have a 
profound impact on the cardiovascular, renal, and nervous systems, which work 
together to regulate blood pressure. The development of SSH and impact of aging 
on blood pressure have been well-established, but the neurophysiological 
mechanisms implicated in SSH and aging, have only been recently explored. 
Objective: To provide mechanistic insight regarding the integrated roles of the 
renal and nervous systems in age-dependent hypertension in male Sprague-
Dawley (SD) rats. 
Methods: Male SD rats of various ages were randomly assigned to various 
experimental protocols. 3-month-old male SD rats were randomly assigned to 
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receive Renal-Capsaicin surgery (Renal-CAP) to ablate the afferent renal nerve 
(ARN) or sham surgery, followed by an acute 5% body weight i.v.-isotonic volume 
expansion protocol (5%-VE) in which natriuretic response and cardiovascular 
functions (HR/MAP) were continuously monitored and analyzed for the duration 
of the experimental period. 3/8/16-month-old male SD rats without Renal-CAP 
surgery were similarly exposed to the 5%-VE protocol. C-fos 
immunohistochemistry (c-Fos IHC) was performed on brain slides prepared from 
rats assigned to the 5%-VE protocol to assess PVN parvocellular neuronal 
activation, as a marker for ARN activity. 3/8/16-month-old male SD rats on 
normal-salt and high-salt (NS/HS; 0.6%/4% sodium chloride respectively) diets 
were assigned to an amiloride and hydrochlorothiazide protocol (AM-HCTZ) to 
evaluate NCC activity, and exposed to i.p. hexamethonium to account for the 
sympathetic contribution to blood pressure. Renal/plasma NE content was 
assessed via ELISA to further account for sympathetic tone. Immunoblotting was 
performed on 3-month-old control saline-infused, s.c.-norepinephrine (NE), and 
s.c.-norepinephrine+terazosin/propranolol male SD rats to assess NCC, 
phosphorylated NCC (pNCCT58), SPAK, WNK1, OxSR1, and phosphorylated 
OxSR1 protein levels, to evaluate the roles of the α1/β-adrenoceptors in the NCC-
implicated ARN-mediated sympathoinhibitory pathway.  
Results: In response to the 5%-VE protocol, the natriuretic response was 
attenuated in Renal-Cap rats. Renal-CAP rats also experienced a significant 
increase in MAP in response to 5%-VE, while sham Renal-CAP rats did not. Both 
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Renal-CAP and sham Renal-CAP rats experienced a significant increase in the 
mean number of PVN Fos-positive cells (Fos+) post-expansion, although the 
increase in Fos+ cells in Renal-CAP rats was smaller in magnitude in comparison 
to their sham Renal-CAP counterpart. An increase in MAP and decrease in 
urinary volume/sodium excretion was observed in male SD rats of increasing age 
in response to 5%-VE. An increase in the mean number of Fos+ cells was 
observed post-expansion in all age groups, while 3-month-old rats experienced a 
larger increase in Fos+ cell count relative to 8-month-old rats.  
 An increase in MAP was observed in rats of increasing age on NS-intake. 
An increase in MAP was also observed in rats of the same age with an increase in 
dietary salt intake from a NS to HS-intake. An increase in MAP drop due to 
hexamethonium was observed in rats on HS-intake and of older age. An increase 
in renal/plasma NE content was observed in rats of increasing age on NS-intake, 
and increases in salt intake in the same age group led to a significant increase in 
NE content. 
An increase in NCC activity was observed in s.c.-NE/Renal-CAP 3-month-
old rats in response to HS-intake, and in rats of increasing age on NS-intake. In 
response to HS-intake, a decrease in NCC activity occurred in rats treated with 
terazosin but not propranolol. Furthermore, a decrease in 
NCC/pNCC/WNK1/pOxSR1 expression was observed in rats treated with 
terazosin in response to HS-intake, whereas protein levels in rats treated with 
propranolol varied independently of dietary salt intake. 
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Conclusion: This present study has provided abundant evidence 
regarding the integrated roles of renal sodium handling and the ARN-mediated 
sympathetic tone in the pathophysiology of age-dependent hypertension in male 
SD rats. Through the demonstration of a hypertensive mechanism, involving an 
impairment of fluid and electrolyte homeostasis that implicates the renal, 
cardiovascular, and nervous systems, this study provides a crucial stepping stone 
for the development of mechanistic treatments for age-dependent hypertension 
in elderly individuals with elevated sympathetic tone. 
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INTRODUCTION 
The Growing Impact of Hypertension 
 Hypertension is defined as having a systolic and diastolic blood pressure 
greater than or equal to 140/90 mmHg respectively (Yoon et al. 2015). It is a 
significant and growing health concern in both the developing and developed 
worlds, such that it has been identified as the leading risk factor for mortality 
(Kearney et al. 2005). An estimated one billion adults worldwide are affected by 
hypertension, and this number is expected to reach 1.5 billion by 2025 (Imprialos 
et al. 2016). According to the Framingham heart study, both men and women 
over the age of 55 have a greater than 90% lifetime risk of developing 
hypertension (Vasan et al. 2002). A standard classification of hypertension is 
shown in Table 1 below.  
Table 1. Classification of hypertension for adult human population. Table taken and 
adapted from Herz (Dorner et al. 2013). 
 
Category SBP (mmHg) DBP (mmHg) 
Optimal <120 (And) <80 
Normal 120–129 (And/or) 80–84 
Above Normal 130–139 (And/or) 85–89 
Stage 1 Hypertension (low) 140–159 (And/or) 90–99 
Stage 2 Hypertension (intermediate) 160–179 (And/or) 100–109 
Stage 3 Hypertension (high)  ≥180 (And/or) ≥110 
Isolated Systolic Hypertension  ≥140 (And) <90 
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Hypertension is also a major risk factor for cardiovascular and kidney 
disease, stroke, premature death, and disability (Frame, Carmichael, and 
Wainford 2016), such that it is responsible for up to 45% of deaths due to heart 
disease and 51% of deaths due to stroke (World Health Organization 2013). In 
fact, mortality rates due to heart disease and stroke double with every 20 mmHg 
increase in systolic blood pressure (SBP) and every 10 mmHg increase in diastolic 
blood pressure (DBP) (Yoon et al. 2015). 
 Hypertension is a medical condition with a myriad of possible causes (e.g. 
dysfunctions in renal mechanisms, sympathetic nervous system, vasculature, 
hormonal levels, renin-angiotensin-aldosterone system (RAAS), and/or the 
endothelin system (Elijovich et al. 2016)), and is due to the existence of many 
moving physiological parts that work in tandem to maintain the normotensive 
state. Cases of hypertension are often categorized as either primary or secondary 
hypertension. In secondary hypertension, there usually exists a distinct cause 
that is responsible for the hypertensive condition. However, the majority of 
hypertensive cases are of the primary nature, in which there exists no clear cause 
(Nadar and Lip 2009). 
 
Impact of Salt on Hypertension 
Salt, namely sodium chloride, is an essential component to one’s daily diet. 
Sodium is a major component of blood pressure regulation, as it is implicated in 
the maintenance of fluid volume. Sodium content is balanced through the 
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involvement of various cardiovascular and renal mechanisms that use ion 
channels, carriers and pumps to move the cation from one location to another. In 
the kidney, the sodium chloride cotransporter (NCC), and the epithelial sodium 
channel (ENaC), located in the renal distal tubules, are crucial in maintaining 
proper sodium balance (Kong et al. 2016). In the normal physiological state, the 
NCC/ENaC transporters allow the reabsorption of sodium from the distal tubule. 
. The sodium balance determines the volume of the extracellular fluid, a critical 
determinant of blood pressure. Dysfunction of one or more mechanisms in blood 
pressure regulation, such as sodium balance or sympathetic tone, often leads to a 
higher risk of abnormal blood pressure. 
The prevalence of hypertension is escalating in large part due to an 
increase in dietary salt intake throughout the world; the current estimated 
dietary salt intake is 9-12 grams per day (g/day) in most countries, significantly 
higher than the 5 g/day recommended by the World Health Organization (Rust & 
Ekmekcioglu, 2016). The effect of dietary salt intake on blood pressure has also 
been well-documented; in the famous INTERSALT study, a 100 mmol increase in 
urinary sodium excretion was shown to correlate with a 3-6 mmHg increase in 
systolic blood pressure (Kjeldsen et al. 2017). Furthermore, in an analysis of the 
impact of salt consumption on cardiovascular disease, a reduction of 2.30 grams 
of sodium per day was associated with a mean arterial pressure (MAP) reduction 
of 3.82 mmHg (Mozaffarian et al. 2014). In addition to its direct effects on blood 
pressure regulation, dietary salt intake is also implicated in other functions of the 
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cardiovascular system, such as endothelial dysfunction, and ventricular 
hypertrophy (Baldo, Rodrigues, and Mill 2015); this in turn may further 
exacerbate the impairment of blood pressure regulation due to salt alone. 
Therefore, hypertension due to dietary salt intake is a definitive global health 
issue. 
 
Pathophysiology of Salt-Sensitive Hypertension 
While numerous studies have identified a correlation between salt intake 
and blood pressure, the blood pressure response to changes in salt intake varies 
considerably among individuals. As shown in figure 1 (Myron H. Weinberger 
1996), increases in dietary salt intake lead to rises in blood pressure in all 
normotensive individuals, but the extent to which blood pressure rises varies 
significantly. Thus, individuals are often divided into salt-sensitive and salt-
insensitive groups; salt-sensitive individuals exhibit increases in blood pressure 
parallel to elevated sodium intake, whereas salt-insensitive individuals maintain 
relatively constant blood pressure levels, regardless of variations in sodium 
intake (Rust and Ekmekcioglu 2016). 
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Figure 1. Percent change in MAP in normotensive subjects receiving incremental 
increases in sodium. Blood pressure at the end of 7 days of low (10 mmol/day) sodium intake 
was taken as baseline. All subjects demonstrated an increase in blood pressure with sodium 
loading, varying from 1.5% to 34%. Figure taken from the Hypertension, American Heart 
Association Journal (Myron H. Weinberger 1996). 
 
 Salt-Sensitive Hypertension (SSH) is estimated to exist in up to 50% of 
hypertensive individuals (Felder et al. 2013). SSH develops due to an impairment 
of normal mechanisms that react to an elevated sodium load in the 
cardiovascular system; an inability to maintain sodium balance results in 
elevated blood pressure via fluid retention involving the RAAS, the actions of the 
antidiuretic vasopressin, and various other mechanisms, to maintain fluid 
volume (Myron H. Weinberger 1996). The specific impairment that leads to SSH 
is highly variable, and can involve a combination of a lack of activation of 
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natriuretic pathways and overactive anti-natriuretic pathways, which result in 
defective physiological mechanisms. 
In particular, the sympathetic nervous system’s interactions with the 
kidney are essential in maintaining proper fluid and electrolyte homeostasis. It 
acts via the neurotransmitter norepinephrine (NE) to increase salt and water 
retention, and thus blood pressure. Multiple studies have implicated NE as a 
contributor to the activation of the sodium chloride cotransporter (NCC) in SSH 
(Terker et al. 2014), and more recently, NE has been shown to prevent a dietary 
sodium-evoked suppression of the NCC, independent of the RAAS (Walsh et al. 
2016).  
 In the kidneys, sodium that reaches the renal distal convoluted tubule is 
reabsorbed through the operation of the NCC and ENaC; thus, an impairment in 
the proper functioning of either transporter may also lead to the development of 
SSH (Pavlov and Staruschenko 2016). Regulation of the NCC in particular 
involves the activation of adrenergic receptors triggered by NE. This in turn leads 
to the activation of a signaling cascade involving the WNK kinases, SPAK kinase, 
and the OxSR1 serine/threonine-protein kinase (Terker et al. 2014); in tandem, 
WNK, SPAK, and OxSR1 are part of a complex kinase network that regulates NCC 
activity and expression via phosphorylation of NCC to pNCC (phosphorylated 
NCC). While previous studies have suggested that β-adrenoceptors stimulate the 
NCC, and that OxSR1 provides an essential role in modulating NCC activity, the 
precise mechanisms surrounding the regulation of the NCC remain unknown 
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(Terker et al. 2014). A proposed schematic representation of NCC regulation is 
provided in figure 2 below. 
Figure 2. Proposed schematic representation of NCC regulation. In this model of NCC 
regulation, the WNK kinases are activated (green arrows; red arrows = inhibition) by aldosterone, 
angiotensin-II (Ang II), decreased salt (NaCl) intake, and increased potassium (K+) intake. The 
WNK kinases use the intermediary SPAK/OxSR1 (OSR1) kinases to mediate phosphorylation, and 
thus activation, of the NCC cotransporter. Figure adapted and taken from Kidney Int. (Johns 
2013). 
 
While the development of SSH and the body’s mechanisms against it have 
been well-established, the neurophysiological mechanisms implicated in 
mediating bodily responses to SSH have only been recently explored. Specifically, 
the renal sympathetic nerves (RSN), and in particular, the afferent renal nerve 
(ARN), has been recently implicated in the long-term regulation of blood 
pressure and pathophysiology of SSH (Johns 2013).  Afferent renal nerves carry 
information from renal chemoreceptors, which respond to sensory mechano- and 
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chemoreceptors in the renal pelvis, leading to a reno-renal reflex that evokes 
sympathoinhibition (Frame, Carmichael, and Wainford 2016). Renal sympathetic 
outflow has been shown to be regulated via the hypothalamic paraventricular 
nucleus (PVN) in fluid volume expansion (Ramchandra et al. 2013), and the ARN 
in particular has also been shown to evoke neural responses in the PVN (Xu et al. 
2015). Moreover, central brain Gα-pathways have been identified as being 
essential in facilitating fluid and sodium homeostasis, and thus normotension, in 
response to acute physiological stresses and/or chronic changes in dietary salt 
intake (Carmichael and Wainford 2015). Dietary high salt (HS) intake has been 
shown to trigger upregulation of Gαq-protein concentrations in the 
paraventricular nucleus (PVN) in Dahl Salt-Sensitive rats, suggesting that their 
salt-sensitive phenotypes may be caused in part by reduced Gαq-protein 
concentrations, which have a critical counter-regulatory role in preventing 
vasopressin hypersecretion in salt-resistant phenotypes (Wainford and Kapusta 
2010). 
 
Impact of Aging on Hypertension 
Aging has been a well-documented risk factor for the development of 
various forms of hypertension (Rust and Ekmekcioglu 2016). The effects of aging 
are multifaceted and complex, and have a profound impact on the proper 
functioning of the cardiovascular, renal, and nervous systems. These various 
organ systems work in tandem to regulate blood pressure, and abnormalities due 
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to aging can affect one or more mechanisms implicated in blood pressure 
regulation, leading to an increase in risk factors associated with hypertension. 
The impact of aging on SSH in particular has been well-documented in the 
aforementioned INTERSALT Study. Salt sensitivity was shown to be positively 
correlated with age, as shown in figure 3, and more so in already hypertensive 
individuals than normotensive one. Moreover, salt-sensitive individuals were 
observed to have an elevated blood pressure significantly higher after 10 years 
when compared with salt-resistant individuals (M. H. Weinberger and Fineberg 
1991). Thus, aging is a major risk factor in the diagnosis and treatment of SSH, 
one that involves various physiological mechanisms. 
Figure 3. Change in salt sensitivity as a function of age in normotensive and 
hypertensive subjects. Salt sensitivity, which increased with age, was measured as the change 
in MAP resulting from sodium depletion following volume expansion. There was a significant 
difference between the salt sensitivity of normotensive (white bars) and hypertensive (dashed 
bars) subjects in the 31-40, 41-50, and 51-60 age groups. Figure taken from Hypertension, 
American Heart Association Journal (M. H. Weinberger and Fineberg 1991). 
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In the cardiovascular system, aging has been associated with arterial 
stiffness, wall thickening due to endothelial dysfunction, and cardiac dysfunction, 
which may all contribute to an inability to properly regulate blood pressure. 
These developments are caused primarily by the loss of smooth muscle cells, 
calcification of the tunica intima and tunica media layers of blood vessels, and 
increased collagen deposition in vessel walls (Dao et al. 2005). As a result, the 
ability of the body to regulate blood pressure deteriorates. 
In the kidneys, aging has been associated with declines in renal function 
with various causes. On average, kidney mass has been observed to decrease by 
10% for each decade of aging past the fifth decade; furthermore, creatinine 
clearance has been shown to decline 30-40% in individuals over the age of 80 
(Duarte, Santos-Araújo, and Leite-Moreira 2011). These observations are often 
caused by disruptions to glomerular filtration (nonfunctional glomeruli, 
glomerulosclerosis), and various fluid/electrolyte disturbances may be caused by 
a decline in activity of both the glomeruli and of the NCC/ENaC transporters as 
well as impairments in renin release by the juxtoglomerular cells (Epstein 1996). 
These factors also contribute to abnormal blood pressure regulation, and may 
potentially lead to SSH. 
While the impact of aging on hypertension has been well-established, 
there remain multiple challenges to the treatment of hypertension in the elderly. 
While multiple studies have suggested benefits for morbidity and mortality with a 
blood pressure reduction to <150/90 mmHg, there is uncertainty concerning the 
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benefits of further reduction, as well as concerning blood pressure guidelines for 
individuals aged 80 or older (Imprialos et al. 2016). As is the case with various 
other disease states, there are also risks associated with polypharmacy and 
comorbidities, which increase with age; this is of particular concern in the 
treatment of hypertension due to the need for treatments involving multiple drug 
classes to obtain aggressive blood pressure goals (Imprialos et al. 2016). Lastly, 
the treatment of hypertension in the elderly also commonly involves essential 
lifestyle modifications, such as the cessation of smoking, alcohol, and increases in 
dieting and exercise. These lifestyle modifications may prove more difficult in 
elderly populations, due again to the presence of comorbidities and other 
potential health-related issues associated with aging (Imprialos et al. 2016). 
 
Goals of Present Study 
 While aging has been definitively associated with the pathogenesis of 
hypertension (Dorner et al. 2013), there remains a lack of knowledge surrounding 
the integrated renal and neural mechanisms involved in regulating sodium 
balance in age-dependent hypertension. Therefore, the present study aims to 
further explore the effect of aging on the regulation of blood pressure, and fluid 
and electrolyte homeostasis in male Sprague-Dawley (SD) rats, to gain novel 
mechanistic insight into the pathophysiology of age-dependent hypertension 
involving the ARN. An analysis was performed regarding the ability of male SD 
rats of various ages to manage acute physiological and pharmacological 
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challenges and on the chronic management of fluid and electrolyte balance, 
which may prove useful in deriving new therapeutic and mechanistic targets for 
the treatment of SSH in humans. 
The ability to excrete water and sodium through urine was evaluated 
among rats of various ages in parallel to young, middle-aged, and elderly human 
ages. Physiologically, acute stresses were presented in the form of volume 
expansion. The activity of the NCC cotransporter was evaluated 
pharmacologically. Norepinephrine (NE) content was also evaluated, and c-Fos 
immunohistochemistry (c-Fos IHC) was performed on various brain slides from 
male SD rats to estimate activation of PVN parvocellular neurons implicated in 
the natriuretic response. In addition, NCC expression and regulation was 
evaluated by immunoblotting to determine the effect of sympathetically-
mediated SSH on levels and expression of the NCC and its regulatory kinases 
(WNK1, OxSR1, SPAK).  
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SPECIFIC AIMS 
 
1. To evaluate the role of the ARN in the sympathoinhibitory and natriuretic 
responses to acute i.v. volume expansion in young (3-month-old) male SD 
rats. 
 
2. To evaluate the effect of age on the sympathoinhibitory reno-renal reflex-
mediated natriuretic response to acute i.v. volume expansion. 
 
3. To evaluate the effect of aging and salt intake (lifelong 0.4% sodium 
chloride normal salt [NS] vs. 21-day 4% sodium chloride high salt [HS] 
intake) on blood pressure, sympathetic tone, and NCC activity. 
 
4. To evaluate the effect of salt intake (lifelong NS vs. 21-day HS-intake) on 
NCC regulation in normal young male SD rats, s.c.-NE infused, and renal-
CAP (33 mM capsaicin solution wrapped around renal artery and vein) 
male SD rats. 
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METHODS 
 Studies were conducted using male Sprague-Dawley (SD) rats supplied 
from Harlan Laboratories (Indianapolis, IN, USA). Rats were individually housed 
in a controlled 20-26oC and 30-70% humidity environment with 12 hour 
light/dark cycles. Rats were randomly assigned to experimental treatment groups 
and fed a normal-salt (NS) diet containing 0.6% sodium chloride (Teklad Global 
Diet, Harlan Laboratories, Indianapolis, IN; Teklad Global 18% protein rodent 
diet no. 2918, 18% protein, 5% crude fat, 5% fiber, 102 mEq Na+/kg) with tap 
water readily available, or a high-salt (HS) diet containing 4% sodium chloride 
(Teklad Global Diet, Harlan Laboratories, Indianapolis, IN; Teklad Global 19% 
protein rodent diet no. 3095, 19% protein, 5% crude fat, 3% fiber, ~696 mEq 
Na+/kg). All experimental protocols were approved by the Institutional Animal 
Care and Use Committee in accordance with the guidelines of the Boston 
University School of Medicine and the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals. Rats were classified by their age group (3-
month-old = young human equivalent, 8-month-old = adult human equivalent, 
16-month-old = old human equivalent), for their designated acute experimental 
protocols (i.v.-isotonic volume expansion or amiloride/hydrochlorothiazide 
infusion), and for all relevant pre-experimental surgical procedures performed 
(Renal-CAP surgery, subcutaneous osmotic minipumps). 
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Afferent Renal Nerve (ARN) Ablation 
 3-month-old male SD rats were randomly assigned to receive Renal-
Capsaicin surgery (Renal-CAP; 33 mM Capsaicin in 5% ethanol, 5% Tween 80 
and 90% normal saline) surgery. In the Renal-CAP surgery, a flank incision was 
made, and the left renal artery and vein were exposed through a small hole in the 
peritoneal membrane. The fat surrounding the renal artery and vein was then 
dissected away, and parafilm was placed under the vessels. A small piece of gauze 
soaked in a capsaicin solution was wrapped around the renal artery and vein for 
15 min. The gauze and parafilm were removed, the area was dried, and the 
procedure was repeated on the contralateral side. 3-month-old male SD rats were 
also randomly assigned to receive sham Renal-CAP surgery, in which the left and 
right renal nerves were visualized through a midline abdominal incision without 
physical disruption of the area. 
 
Subcutaneous Osmotic Minipump Implantation 
Rats were supplied with a subcutaneous osmotic minipump containing a 
control saline, NE, NE/terazosin, or NE/propranolol at 10 mg/kg/day prior to 
their dietary assignments. Rats designated for osmotic minipump implantation 
were anesthetized with sodium methohexital (20mg/kg i.p.) and surgically 
instrumented with an osmotic minipump (Alzet, osmotic pump model 2ML2, 
Palo Alto, CA, USA) placed subcutaneously (s.c.) in the subscapular region. 
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Following implantation, all rats were returned to their home cage following 
administration of penicillin (300,000 units/ml, 0.3ml). 
 
Acute Surgical Procedure 
On the day of the study, rats were anesthetized with sodium methohexital 
(20 mg/kg i.p. supplemented with 10 mg/kg i.v. as required), and surgical 
implantation of cannulae for the left femoral vein, artery, and bladder, were 
subsequently performed to allow for intravenous infusions, measurement of 
heart rate (HR) and mean arterial pressure (MAP), and collection of plasma and 
urine samples for collection of data regarding renal function. 
 Following surgical cannulation, rats were placed in a Plexiglas holder and 
i.v-infused isotonic saline (20 µL/min) was maintained for a 2 hour surgical 
recovery period prior to the start of each experimental protocol; this allowed the 
rat to regain full consciousness, and to stabilize its cardiovascular and renal 
functions. 
 During the experimental period, HR/MAP were continuously recorded 
using a BIOPAC data acquisition software (MP150 and ACKNOWLEDGE 3.8.2, 
BIOPAC Systems, Inc, Goleta, CA, USA) connected to an external pressure 
transducer (P23XL; Viggo Spectramed, San Francisco, CA, USA), and urine was 
collected in 10-minute intervals throughout the duration of the experiment. 
Following the recovery period, rats were treated with an acute physiological or 
pharmacological challenge in the form of 5% body weight i.v.-isotonic volume 
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expansion (5% VE) or i.v.-amiloride and hydrochlorothiazide infusion (AM-
HCTZ). 
 
Acute Volume Expansion Protocol 
 For the 5%-VE experimental protocol, HR/MAP were first recorded 
continuously over a 20-minute control period (20 µL/min i.v.-isotonic saline). 
This was followed by a 30-minute expansion period in which isotonic saline was 
infused intravenously equivalent to 5% of the rat’s body weight. This was 
followed by a 90-minute recovery period in which i.v.-isotonic saline was again 
infused at a baseline rate of 20 µL/min. 
 
NCC Activity Protocol 
 For the NCC Activity experimental protocol, HR/MAP were first recorded 
continuously over a 60-minute control period (20 µL/min i.v.-isotonic saline). 
This was followed by an i.v. infused bolus of amiloride (2 mg/kg) used to block 
the ENaC, and a 60-minute period of continuous i.v. amiloride infusion (2 mg/kg 
at 20 µL/min). This was followed by an i.v.-infused bolus of a combined 
amiloride and hydrochlorothiazide solution (2 mg/kg) and a 60-minute period of 
continuous i.v.-amiloride/hydrochlorothiazide infusion (2 mg/kg at 20 µL/min). 
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Sympathetic Nervous System Protocol 
  Following completion of the AM-HCTZ experimental protocol, the peak 
change in MAP (ΔMAP) in response to hexamethonium (30 mg/kg i.p.) was 
assessed. Baseline MAP was determined as the average MAP recorded over a 10 
minute control period prior to i.p. hexamethonium injection. Post-injection, MAP 
was monitored for an additional 30 minute period. The peak depressor response 
was assessed over the post-injection time period, and occurred within 1 minute of 
the injection. 
 
Post-Acute Experimental Protocol Data Analysis 
All measurements performed on acute studies were compiled and 
calculated via Microsoft Excel. Analysis of sodium and potassium urine and 
plasma content was conducted using a flame photometer (model 943; 
Instrumentation Laboratories, Bedford, MA). Analysis of urine and plasma 
osmolality was conducted using a vapor pressure osmometer (Vapro 5600, 
Wescor, Logan, UT). Urine volume was determined gravimetrically assuming 1g 
= 1ml.  HR/MAP were monitored and recorded continuously throughout the 
experimental protocol. Renal and plasma NE levels were determined via ELISA 
(Immuno-Biological Labs America, Minneapolis, MN; cat. no. IB89552). 
In the AM-HCTZ protocol, the peak natriuretic response (ΔUNaV; 
μeq/min) was determined by subtracting the baseline UNaV value from the 
maximum natriuretic value observed during each hour of drug infusion (i.v.-
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amiloride or i.v.-amiloride and hydrochlorothiazide). Baseline UNaV values were 
determined by averaging the UNaV values from the last two 10-min time points 
during the previous hours of the study; for the amiloride period, baseline hours 
were taken from the 40–50 min/50–60 min isotonic saline time slots, and for the 
amiloride-hydrochlorothiazide period, from the 100–110 min/110–120 min IV-
amiloride time slots. 
 
Post-Acute Experimental Protocol Studies  
Following acute protocol completion, rats were either decapitated while 
conscious, allowing for the collection of both kidneys, which were immediately 
frozen at −80°C, or rats were deeply anesthetized with sodium methohexital 
(10 mg/kg i.v.) and immediately perfused transcardially with 0.2–0.3L of 
0.1 m phosphate‐buffered saline (PBS) followed by 4% paraformaldehyde (PFA) 
in 0.1 m PBS (4°C, 0.3–0.5L). 
 
C-Fos Immunohistochemistry (c-Fos IHC) Studies 
Rat brains were removed and placed in a vial containing 4% PFA in PBS 
overnight and then switched to a 30% w/v sucrose solution for 2 days. The PVN 
was sectioned into three separate sets of serial 40‐μm coronal sections that were 
collected into a cryoprotectant (30% sucrose + 30% ethylene glycol + 1% 
polyvinyl‐pyrrolidone in 0.1M PBS) and stored at −20°C until they were 
processed for immunohistochemistry. 
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Free‐floating sections from each brain were processed for c-Fos IHC using 
a rabbit polyclonal anti‐Fos antibody (Calbiochem, San Diego, CA, USA). Sections 
were briefly brought to room temperature and rinsed twice for 30 min in 
0.1M PBS to remove cryoprotectant. Sections were incubated in 0.3% hydrogen 
peroxide in distilled water for 30 minutes at room temperature and then rinsed 
for 30 minutes in 0.1M PBS. Sections were then incubated for 2 hours at room 
temperature in PBS diluent (3% normal horse serum in 0.1M PBS containing 
0.25% Triton‐100; Sigma‐Aldrich). The rabbit polyclonal anti‐Fos antibody was 
diluted to 1:30,000 in PBS diluent, and the sections were incubated in the 
primary antibody for 2 days at 4°C. After two 30 minutes rinses in 0.1M PBS, 
sections were incubated in a biotinylated horse anti‐rabbit IgG (Vector 
Laboratories, Burlingame, CA, USA) diluted to 1:200 in PBS diluent for 2 hours 
at room temperature. The tissue was reacted with an avidin–peroxidase 
conjugate (ABC‐Vectastain kit; Vector Laboratories) and PBS containing 0.04% 
3,3′‐diaminobenzidene hydrochloride and 0.04% nickel ammonium sulphate 
(Sigma‐Aldrich). Sections were mounted on gel‐coated slides, processed through 
a series of dehydrating alcohols followed by xylenes, and placed under a coverslip 
with Permount mounting medium. 
Tissue sections were analyzed using an Olympus microscope (BX41) 
equipped for epifluorescence and an Olympus DP70 digital camera with dp 
manager software (v 2.2.1) (Olympus, Center Valley, PA, USA). The PVN was 
identified using a stereotaxic atlas (Paxinos & Watson, 1998, The Rat Brain in 
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Stereotaxic Coordinates, San Diego, CA) and sampled at three rostral–caudal 
levels (Stocker, Cunningham, and Toney 2004). Care was taken to ensure that the 
sections used were from the same rostral–caudal plane in each brain. Analysis 
was performed on two sets of tissue for each animal. The number of Fos‐positive 
cells was visually quantified by participants blind to the experimental conditions 
using National Institute of Health image software (NIH, Bethesda, MD, USA), 
and the counts for each PVN subnucleus was averaged for each animal. 
 After designated acute experimental protocols, rats were sacrificed and 
kidneys were immediately extracted, harvested, and stored at -80oC. 
Approximately 200 mg of kidney cortical tissue was homogenized on ice using 
hand-held pestles and 1.5 ml microcentrifuge tubes containing a homogenizing 
buffer consisting of 10 mM triethanolamine, 250 mM sucrose, 100 mM NaN3, 10 
mM PMSF, and 1 mM leupeptin. The resulting homogenate was centrifuged at 
4,000 g for 10 minutes at 4°C. The supernatant was collected and centrifuged at 
17,000 g for 60 minutes at 4°C. Following centrifugation, the membrane pellet 
was resuspended in 400 μl of homogenizing buffer, and protein content was 
quantified via BCA assay. Membrane preparations were stored at −80°C prior to 
use in western blotting studies. 
 
Immunoblotting Studies 
For the immunoblotting, protein extracted from membrane preparations 
of kidney cortex tissue were loaded at a concentration of 40 μg of protein per 
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lane. Membranes were blocked in 5% milk for 1 hour and probed overnight at 4°C 
with anti-NCC (1:2,000; Millipore, Billerica, MA; cat. no. AB3553), anti-wnk1 
(1:200; Santa Cruz Biotechnology, Santa Cruz, CA; cat. no. SC20470), anti-SPAK 
(1:1000; Abcam; cat. no. AB79045), anti-OxSR1 (1:1000; Abcam; cat. no. 
AB74003), anti-pNCCT58 (1:1000; (Lee et al. 2013)), or anti-pOxSR1 (1:1000; 
Abcam; cat. No. AB138655) primary antibody in 0.1% PBS-Tween. On the next 
day, membranes were exposed to a secondary horseradish peroxidase (HRP) 
donkey anti-rabbit IgG (1:5,000; Promega, Madison, WI; cat. no. V7951) in 0.1% 
PBS-Tween for 1 hour at room temperature. Blots were subsequently exposed to 
ECL reagent for 5 minutes, then bound antibodies were visualized using 
chemiluminescence (GE signal enhancer; GE, Buckinghamshire, UK). 
Densitometric analysis was performed using Quantity One software (Bio-Rad, 
Hercules, CA). All immunoreactive bands were normalized to β-Actin (1:1000, 
A2228, Sigma) and semi-quantified via the Quantity One software. 
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RESULTS 
 
ARN Ablation and Acute Volume Expansion 
 Natriuresis in response to a 5% body weight i.v.-isotonic volume expansion 
(5%-VE) was significantly attenuated (p<0.05) in selective afferent renal nerve 
(ARN; via Renal-CAP protocol) ablated 3-month-old male SD rats in comparison 
to their sham counterpart (figure 4). Additionally, Renal-CAP rats experienced a 
significant increase (p<0.05) in MAP in response to 5%-VE relative to control 
baseline values, while sham Renal-CAP rats did not. 
 
Figure 4. Effect of afferent renal nerve (ARN) ablation via the Renal-CAP protocol 
on changes in MAP, urine output (V; µL/min), and natriuresis (UNaV; µEq/min) in 
response to a 5% body weight i.v.-isotonic volume expansion. *: p<0.05 vs. respective 
group/control baseline values; τ: p<0.05 vs. respective sham Renal-CAP counterpart. 
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 Both Renal-CAP and sham Renal-CAP rats experienced a significant 
increase (p<0.05) in the mean number (per section) of Fos-positive parvocellular 
nuclei (Fos+) in all PVN subregions in response to volume expansion, relative to 
their respective group control/baseline counterparts (figures 5 and 6). However, 
the increase in Fos+ cell count post-expansion in Renal-CAP rats was smaller in 
magnitude in comparison to their sham Renal-CAP counterpart, such that 5%-VE 
exposed Renal-CAP rats exhibited a significant decrease (p<0.05) in Fos+ cells in 
all PVN subregions relative to its 5%-VE sham Renal-CAP counterpart. 
 
Figure 5. Mean Fos-positive (Fos+) PVN nuclei averaged across all rostral-caudal 
levels at baseline & 120 minutes post 5%-VE. *: p<0.05 vs. respective group/control 
baseline values; τ: p<0.05 vs. respective sham Renal-CAP counterpart. DP = dorsal parvocellular, 
MP = medial parvocellular, VLP = ventrolateral parvocellular, LP = lateral parvocellular 
 
 
 
 
 
 
 25 
Figure 6. Representative images of sham and Renal-CAP pre- and post-5%-VE PVN 
Fos+ nuclei. 3V = third ventricle. 
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Age-Dependent Acute Volume Expansion 
An increase in MAP was observed in male Sprague-Dawley (SD) rats of 
increasing age (figure 7). A significant increase (p<0.05) was observed between 
the MAP of 8-month-old rats in comparison to its 3-month-old counterpart 
(p<0.05) and between the MAP of 16-month-old rats in comparison to their 8-
month-old counterpart. However, there was no observed change in MAP in male 
SD rats of any age in response to 5%-VE. 
Figure 7. Effect of age on MAP in response to a 5% body weight i.v.-isotonic volume 
expansion. τ: p<0.05 vs. respective 3-month-old counterpart; #: p<0.05 vs. respective 8-
month-old counterpart. 
 
An increase in urinary volume excretion was observed in male SD rats of 
all ages in response to a 5%-VE (figure 8). However, a significant decrease 
(p<0.o5) was observed between the percent of urine load excreted of both 8/16-
month-old rats when compared to their respective 3-month-old counterparts and 
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between the percent of urine load excreted of 16-month-old rats in comparison to 
their 8-month-old counterpart, during the recovery period. 
Figure 8. Effect of age on urinary volume excretion (measured as percent of load 
excreted) in response to a 5% body weight i.v.-isotonic volume expansion. τ: p<0.05 
vs. respective 3-month-old counterpart; #: p<0.05 vs. respective 8-month-old counterpart. 
 
 An increase in urinary sodium excretion was observed in male SD rats of 
all ages in response to a 5%-VE (figure 9). However, a significant decrease 
(p<0.05) was observed between the percent of sodium load excreted of both 
8/16-month-old rats when compared to their respective 3-month-old 
counterparts and between the percent of sodium load excreted of 16-month-old 
rats in comparison to their 8-month-old counterpart, during the recovery period. 
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Figure 9. Effect of age on urinary sodium excretion (measured as percent of sodium 
load excreted) in response to a 5% body weight i.v.-isotonic volume expansion. τ: 
p<0.05 vs. respective 3-month-old counterpart; #: p<0.05 vs. respective 8-month-old 
counterpart. 
 
Age-Dependent PVN Activation 
At baseline prior to volume expansion, no difference was observed in the 
mean number of Fos-positive parvocellular nuclei (Fos+) at all rostral-caudal 
levels between 3 and 8 month-old groups (figures 10 and 11). Following volume 
expansion, the Fos+ cell count was significantly higher (p<0.05) in 3-month-old 
male SD rats relative to their 8/16-month-old counterparts. This difference was 
most pronounced in the medial parvocellular (MP) level of the PVN. 
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Figure 10. Mean number (per section) of baseline and 120-minute post-expansion 
Fos-positive parvocellular nuclei averaged across all rostral-caudal levels. *: p<0.05 
vs. respective baseline value; τ: p<0.05 vs. respective 3-month-old counterpart at same time 
point; #: p<0.05 vs. respective 8-month-old counterpart at same time point. DP = dorsal 
parvocellular, MP = medial parvocellular, VLP = ventrolateral parvocellular, LP = lateral 
parvocellular. ND = not determined. 
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Figure 11. Representative images of PVN fos-positive nuclei in male Sprague-Dawley 
rats aged 3, 8, and 16 months at baseline and 120 minutes post-volume expansion. 
3V = third ventricle. 
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Aging and Salt Intake 
 An increase in MAP was observed in male SD rats of increasing age (figure 
12). Furthermore, an increase in MAP was observed in male SD rats of the same 
age with an increase in dietary salt intake from a NS to HS-intake. A significant 
increase (p<0.o5) was observed between the MAP of both NS/HS-intake 8-
month-old rats when compared to their respective NS/HS-intake 3-month-old 
counterparts. A significant increase (p<0.05) was also observed between the MAP 
of 16-month-old NS-intake rats when compared to its 8-month-old NS-intake 
counterpart.  
Figure 12. Effect of lifelong normal salt (NS; 0.6% NaCl) vs. 21-day high salt (HS; 4% 
NaCl) intake on MAP in 3/8/16-month-old male SD rats. τ: p<0.05 vs. respective 3-
month-old counterpart; #: p<0.05 vs. respective 8-month-old counterpart. ND = not determined. 
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An increase in the MAP drop (ΔMAP) due to hexamethonium (i.p. 30 
mg/kg) was observed in male SD rats of older age on NS-intake (figure 13) 
relative to its 3-month-old counterpart. HS-intake in 3-month-old rats led to a 
significant decrease in ΔMAP (p<0.05) relative to its NS-intake counterpart. 
However, HS-intake in the older 8-month-old rats did not lead to a decrease in 
ΔMAP in comparison to its NS-intake counterpart. 
 
Figure 13. Peak ΔMAP to i.p. hexamethonium in 3/8/16-month-old male Sprague-
Dawley rats on NS/HS diets. *: p<0.05 vs. respective 3-month-old NS control value; τ: 
p<0.05 vs. respective 3-month-old counterpart. ND = not determined. 
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An increase in renal NE content was observed in male SD rats of 
increasing age on NS-intake (figure 14). HS-intake in 3-month-old rats led to a 
significant decrease (p<0.05) in renal NE content relative to its 3-month-old NS-
intake counterpart. However, HS-intake in the older 8-month-old rats did not 
alter renal NE content significantly, in comparison to its NS-intake counterpart. 
 
Figure 14. Renal norepinephrine content in 3/8/16-month-old male Sprague-Dawley 
rats on NS/HS diets. Renal NE content was determined via ELISA. *: p<0.05 vs. respective 3-
month-old NS control value; τ: p<0.05 vs. respective 3-month-old counterpart; #: p<0.05 vs. 
respective 8-month-old counterpart. ND = not determined. 
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An increase in plasma NE content was observed in male SD rats of 
increasing age on NS-intake (figure 15). HS-intake in 3-month-old rats led to a 
significant decrease (p<0.05) in plasma NE content relative to its 3-month-old 
NS-intake counterpart. However, HS-intake in the older 8-month-old rats did not 
alter plasma NE content significantly, in comparison to its NS-intake 
counterpart.  
 
Figure 15. Plasma norepinephrine content in 3/8/16-month-old male Sprague-
Dawley rats on NS/HS diets. Plasma NE content was determined via ELISA. *: p<0.05 vs. 
respective 3-month-old NS control value; τ: p<0.05 vs. respective 3-month-old counterpart. ND = 
not determined. 
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Salt Sensitivity of Blood Pressure 
 No change in MAP was observed in control s.c.-saline male SD rats in 
response to HS-intake. However, a significant increase (p<0.05) in MAP was 
observed in s.c.-NE and Renal-CAP 3-month-old male SD rats in response to HS-
intake, relative to their NS-intake counterparts (figure 16). A significant increase 
(p<0.05) in MAP was also observed in NS-intake 8-month-old rats relative to its 
3-month-old counterpart, and in NS-intake 16-month-old rats relative to its 8-
month-old counterpart. 
 
Figure 16. Effect of lifelong normal salt (0.6% NaCl) intake vs. high salt (4% NaCl for 
21 days) intake on MAP in male SD rats of various ages and aging models. *: p<0.05 
vs. respective normal salt value; τ: p<0.05 vs. respective 3-month-old counterpart; #: p<0.05 vs. 
respective 8-month-old counterpart. ND = not determined. 
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HS-intake in 3-month-old s.c.-saline male SD rats led to a significant 
decrease (p<0.05) in NCC activity (figure 17), whereas HS-intake in salt-sensitive 
s.c.-NE and Renal-CAP rats did not. A significant increase (p<0.05) in NCC 
activity was also observed in NS-intake 8-month-old and 16-month-old rats in 
comparison to its 3-month-old counterpart. However there was no significant 
decrease in NCC activity of 8-month-old rats with HS-intake compared with 
same age NS-intake.  
 
Figure 17. Effect of lifelong normal salt (0.6% NaCl) intake vs. high salt (4% NaCl for 
21 days) intake on NCC activity (measured as peak natriuresis to i.v. HCTZ infusion) 
in male SD rats of various ages and aging models. *: p<0.05 vs. respective normal salt 
value; τ: p<0.05 vs. respective 3-month-old counterpart; #: p<0.05 vs. respective 8-month-old 
counterpart. ND = not determined, HTN = hypertension. 
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α1/β-Adrenoceptor Antagonism 
 In control s.c.-saline 3-month-old male SD rats, neither treatment with 
terazosin nor propranolol led to changes in MAP. In s.c.-NE-infused rats, 
treatment with terazosin led to a significant decrease (p<0.05) in MAP in 
response to HS-intake relative to its non-terazosin-treated counterpart, whereas 
treatment with propranolol resulted in a lower MAP independent of diet. In 16-
month-old rats, treatment with terazosin led to a significant decrease (p<0.05) in 
MAP in response to HS-intake, relative to its naïve counterpart. 
 
Figure 18. Effect of lifelong normal salt (0.6% NaCl) intake vs. high salt (4% NaCl for 
21 days) intake on MAP in male SD rats of various ages/models receiving s.c. 
terazosin (10 mg/kg/day) or propranolol (9.9 mg/kg/day). *: p<0.05 vs. respective 
control normal salt counterpart; ф: p<0.05 vs. respective s.c. saline counterpart; τ: p<0.05 vs. 
respective high-salt counterpart; #: p<0.05 vs. respective 3-month-old naïve counterpart. NE = 
norepinephrine, Pro = propranolol, Teraz = terazosin. 
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In control s.c.-saline 3-month-old male SD rats, a significant decrease 
(p<0.05) in NCC activity was observed in response to HS-intake, both with and 
without treatment with terazosin or propranolol. In s.c NE-infused rats, 
treatment with terazosin also resulted in a significant decrease (p<0.05) in NCC 
activity relative to its NS-intake counterpart, whereas treatment with propranolol 
did not. In 16-month-old rats, treatment with terazosin also resulted in a 
significant decrease (p<0.05) in NCC activity relative to its naïve counterpart. 
Figure 19. Effect of lifelong normal salt (0.6% NaCl) intake vs. high salt (4% NaCl for 
21 days) intake on NCC activity (measured as peak natriuresis to i.v. HCTZ) in male 
SD rats of various ages/models receiving s.c. terazosin (10 mg/kg/day) or 
propranolol (9.9 mg/kg/day). *: p<0.05 vs. respective control normal salt counterpart; τ: 
p<0.05 vs. respective high-salt counterpart; #: p<0.05 vs. respective 3-month-old naïve 
counterpart. NE = norepinephrine, Pro = propranolol, SHR = spontaneously hypertensive rat, 
Teraz = terazosin. 
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Immunoblotting 
Figure 20. Sample immunoblots in saline and NE-infused 3-month-old male SD 
rats. Band densities were normalized to β-actin. 
 
  
In control saline male SD rats, HS-intake resulted in a significant decrease 
(p<0.05) in NCC and pNCC expression relative to its NS-intake counterpart. 
(figures 20, 21, and 22). In s.c. NE-infused rats, no difference in NCC and pNCC 
expression was observed in response to HS-intake. However, HS-intake NCC and 
pNCC expression was significantly higher (p<0.05) relative to its control saline 
counterpart. Treatment with terazosin resulted in a significant decrease (p<0.05) 
in NCC and pNCC expression relative to its NS-intake counterpart. However, 
treatment with propranolol did not lead to changes in NCC/pNCC expression in 
response to HS-intake. 
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Figure 21. Renal NCC protein levels in saline and NE-infused 3-month-old male SD 
rats. *: p<0.05 vs. respective control normal salt counterpart; τ: p<0.05 vs. respective high-salt 
counterpart; ф: p<0.05 vs. respective s.c. saline counterpart. Pro = propranolol, Teraz = 
terazosin. 
 
Figure 22. Renal phosphorylated NCC (pNCCT58) protein levels in saline and NE-
infused 3-month-old male SD rats. *: p<0.05 vs. respective control normal salt counterpart; 
τ: p<0.05 vs. respective high-salt counterpart; ф: p<0.05 vs. respective s.c. saline counterpart. 
Pro = propranolol, Teraz = terazosin. 
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In control saline male SD rats, HS-intake resulted in a significant decrease 
(p<0.05) in SPAK expression relative to its NS-intake counterpart. (figures 20 
and 23). In s.c. NE-infused rats, a slight increase in SPAK expression was 
observed in response to HS-intake. HS-intake SPAK expression was also 
significantly higher (p<0.05) relative to its control saline counterpart. Treatment 
with either terazosin or propranolol resulted in a significant decrease in 
NCC/pNCC expression relative to its NS-intake counterpart. 
 
Figure 23. Renal SPAK protein levels in saline and NE-infused 3-month-old male SD 
rats. *: p<0.05 vs. respective control normal salt counterpart; τ: p<0.05 vs. respective high-salt 
counterpart; ф: p<0.05 vs. respective s.c. saline counterpart. Pro = propranolol, Teraz = 
terazosin. 
 
In control saline male SD rats, HS-intake resulted in a significant decrease 
(p<0.05) in WNK1 expression relative to its NS-intake counterpart. (figures 20 
and 24). In s.c. NE-infused rats, no difference in WNK1 expression was observed 
in response to HS-intake. However, HS-intake WNK1 expression was 
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significantly higher (p<0.05) relative to its control saline counterpart. Treatment 
with terazosin resulted in a significant decrease in WNK1 expression in response 
to HS-intake relative to its control saline NS-intake counterpart. However, 
treatment with propranolol did not lead to changes in WNK1 expression in 
response to HS-intake. 
 
Figure 24. Renal WNK1 protein levels in saline and NE-infused 3-month-old male 
SD rats. *: p<0.05 vs. respective control normal salt counterpart; τ: p<0.05 vs. respective high-
salt counterpart; ф: p<0.05 vs. respective s.c. saline counterpart. Pro = propranolol, Teraz = 
terazosin. 
 
 
In control saline male SD rats, HS-intake resulted in a significant decrease 
(p<0.05) in OxSR1 expression relative to its NS-intake counterpart. (figures 20 
and 25). In s.c. NE-infused rats, a significant increase (p<0.05) in OxSR1 
expression was observed relative to its control saline counterpart, independent of 
diet. Treatment with terazosin resulted in a significant decrease in OxSR1 
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expression independent of diet. However, treatment with propranolol did not 
lead to changes in OxSR1 expression. 
 
Figure 25. Renal OxSR1 protein levels in saline and NE-infused 3-month-old male 
SD rats. *: p<0.05 vs. respective control normal salt counterpart; τ: p<0.05 vs. respective high-
salt counterpart; ф: p<0.05 vs. respective s.c. saline counterpart. Pro = propranolol, Teraz = 
terazosin. 
 
In control saline male SD rats, HS-intake resulted in a significant decrease 
(p<0.05) in pOxSR1 expression relative to its NS-intake counterpart. (figures 20 
and 26). In s.c. NE-infused rats, an increase in pOxSR1 expression was observed 
in response to HS-intake. HS-intake pOxSR1 expression was also significantly 
higher (p<0.05) relative to its control saline counterpart. Treatment with 
terazosin resulted in a significant decrease in pOxSR1 expression in response to 
HS-intake. However, treatment with propranolol did not lead to changes in 
pOxSR1 expression in response to HS-intake. 
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Figure 26. Renal pOxSR1 protein levels in saline and NE-infused 3-month-old male 
SD rats. *: p<0.05 vs. respective control normal salt counterpart; τ: p<0.05 vs. respective high-
salt counterpart; ф: p<0.05 vs. respective s.c. saline counterpart. Pro = propranolol, Teraz = 
terazosin. 
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DISCUSSION 
  
ARN Ablation and Acute Volume Expansion 
ARN ablation (via the Renal-CAP protocol) in young 3-month-old male 
Sprague-Dawley (SD) rats resulted in an attenuation of natriuresis and 
sympathoinhibitory PVN parvocellular neuron activation, as well as increased 
MAP during i.v.-isotonic volume expansion. This observation is in agreement 
with previous studies implicating the ARN in elevated sympathetic tone (Patel 
and Knuepfer 1986). The data also suggests that the mechanosensitive ARN may 
contribute to the regulation of natriuresis and MAP via a PVN-implicated 
sympathoinhibitory reno-renal reflex. This suggestion is also in agreement with 
previous studies that implicate renal denervation of both the efferent and afferent 
nerves, as opposed to selective ARN ablation, in the reduction of blood pressure 
(Foss, Fink, and Osborn 2016). 
 
Age-Dependent Acute Volume Expansion 
In the acute isotonic volume expansion studies involving male SD rats of 
varying ages, the data suggest that the hypertensive state in adult (8-month) and 
aged (16-month) male SD rats may be due to an impaired ability to excrete fluid 
and sodium through the urine. The attenuated natriuretic response in adult and 
aged male SD rats with age-dependent hypertension may be due to an inhibition 
of the aforementioned sympathoinhibitory reno-renal reflex that acts to mediate 
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natriuresis. This is also supported by the observation of attenuated PVN neuronal 
activation identified by the mean number of Fos+ parvocellular nuclei, which 
suggests a decrease in sympathoinhibitory signal propagation via the ARN in 
response to acute volume expansion in older male SD rats. Collectively, the data 
significantly suggests that age-dependent hypertension in male SD rats 
progressively results in an attenuated sympathoinhibitory reno-renal reflex-
mediated natriuresis, as well as a decreased in PVN neuronal activation, in 
response to acute 5%-VE. The data is in agreement with various prior studies that 
historically relate sympathetic nervous system dysfunction with the pathogenesis 
of hypertension (Mancia and Grassi 2014). 
 
Aging and Salt Intake 
The observation of increased MAP in older male SD rats on lifetime NS-
intake in conjunction with an increased sympathetic tone suggests that their age-
dependent hypertension may be due to a lack of sympathoinhibition. 
Hexamethonium is a known ganglionic blocker that as expected, led to a 
depressor response in all rat groups (Walsh et al. 2016). As a ganglionic blocker, 
i.p. hexamethonium served as an indicator of the contribution of sympathetic 
tone to the overall MAP. Thus, the elevated depressor response due to i.p. 
hexamethonium in older male SD rats further suggests that their age-dependent 
hypertension may be due to an increase in sympathetic tone. This is further 
suggested by the lack of sympathoinhibition (elevated renal/plasma NE, elevated 
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ΔMAP to i.p. hexamethonium) observed in HS-intake adult (8-month-old) male 
SD rats. 
As previously mentioned, NE has been shown to contribute towards NCC 
regulation (Terker et al. 2014), and more specifically, to act towards preventing a 
dietary sodium-evoked suppression of the NCC (Walsh et al. 2016). Thus, the 
observation of a lack of sympathoinhibition may be due to changes in NCC 
expression and activity, which was evaluated in subsequent studies. 
 
Salt Sensitivity of Blood Pressure 
 In the salt-sensitivity studies, the data suggest that young 3-month-old 
male SD rats maintain normotension via downregulation of NCC activity and 
expression in response to elevated sodium intake; this is suggested by the parallel 
decrease in both NCC and phosphorylated NCC levels in s.c.-saline male SD rats. 
In the NE-infused rats, used as a model of age-related increases in sympathetic 
tone, there is a failure to downregulate NCC activity in response to HS-intake, 
suggesting that NCC activity serves a critical role in the pathophysiology of SSH 
in young male SD rats. In the Renal-CAP male SD rat, another model of 
sympathoexcitation caused by attenuation of sympathoinhibitory influence from 
the ARN, there is also a failure to reduce NCC activity in response to HS-intake, 
suggesting a critical connection between ARN-mediated sympathetic tone and 
NCC activity. These aging and sympathoexcitation models coincide with the 
observation of increased NCC activity in the adult/aged 8/16-month-old male SD 
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rats, further suggesting an age-related dysfunction involving ARN-mediated 
sympathetic tone and NCC activity. In addition, the observation of higher MAP 
and HCTZ-induced natriuresis in older male SD rats on a NS diet suggests an 
increase in basal NCC activity in age-dependent hypertension. This further 
suggests the involvement of sympathetic tone in NCC activity and regulation, and 
in the overall pathogenesis of age-dependent hypertension in the older male SD 
rats. 
 
α1/β-Adrenoceptor Antagonism 
 α1 and β-adrenoceptor antagonism (via terazosin and propranolol 
respectively) did not affect NCC activity or regulation in control saline-infused 
young 3-month-old male SD rats. However, α1-antagonism significantly 
decreased MAP and NCC activity in aged 16-month-old male SD rats with 
established hypertension. Furthermore, α1-antagonism in young NE-infused male 
SD rats resulted in the abolishment of salt-sensitivity of MAP (as indicated by 
similar MAP in both s.c.-NE/terazosin NS/HS groups) as well as the restoration 
of HS-intake-dependent NCC downregulation. Collectively, this suggests that the 
α1-adrenoreceptor is implicated in the regulation of the sympathetically-mediated 
NCC activity, which is involved in the development of age-dependent 
hypertension. This challenges the suggestion in recent studies that suggests 
sympathetically-mediated NCC activity acts via the β-adrenoceptor (Terker et al. 
2014). 
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 The immunoblotting studies suggest that in young NE-infused male SD 
rats, the restoration of HS-intake induced NCC downregulation via α1-
antagonism, accompanied by the downregulation of WNK1 expression, operates 
via a mechanism that hinders OxSR1 upregulation and phosphorylation. While β-
antagonism also abolished NE-induced hypertension in young male SD rats, it 
did so independently of salt-intake, suggesting that the β-adrenoceptor may not 
be directly involved in the aforementioned age-dependent hypertension seen in 
aged male SD rats. This is further suggested by the lack of suppression of NCC, 
WNK1, or OxSR1 activity due to HS-intake in s.c.-NE/propranolol-infused male 
SD rats. Collectively, the data suggest that the lack of NCC activation implicated 
in age-dependent hypertension may be due to abnormalities in the α1-
adrenoreceptor pathway, which involves WNK1, SPAK, and OxSR1 expression. 
The data contributes novel insight into the suggestion in previous studies that the 
WNK, SPAK, and OxSR1 kinases are all involved in NCC regulatory responses to 
changes in salt intake (Vallon 2008). 
 
Limitations and Alternative Strategies 
 While this present study has soundly suggested a role of the ARN in 
mediating the sympathoinhibitory and natriuretic responses to an acute 
challenge in fluid and electrolyte balance in the form of 5%-VE, as well as in 
preventing the development of SSH in young male SD rats, it may be limited by 
the lack of available mechano- or chemoreceptor pharmacological antagonists to 
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support the premise that such receptors are activated and thus affecting the ARN. 
Therefore, an additional alternative strategy is to incorporate the use of such 
receptor antagonists, when available. While c-Fos IHC is considered an 
established method of assessing neuronal activation (Sundquist and Nisenbaum 
2005), it is still not without certain limitations, such as the lack of a phenotype 
for labelled cells. Thus, future alternative strategies may also use additional 
methods to account for c-Fos IHC limitations in data analysis, through 
consultation and collaboration with experts in c-Fos IHC analysis. 
 This present study has also suggested that the sympathetically-mediated 
age-dependent hypertension in male SD rats acts via α1-adrenoceptor-gated NCC 
activity. However, while the isolation of the NCC cotransporter via ENaC 
blockade prior to and during NCC antagonism has been widely accepted and 
reproduced, as is the assessment of NCC phosphorylation (Pedersen et al. 2010), 
such techniques provide markers of NCC activity, without directly assessing NCC-
mediated sodium transport. Thus, future considerations and experiments should 
make use of alternative and more explicit methods of measuring sodium 
transport via the NCC, once available. 
  
Significance and Future Considerations 
 This present study has provided abundant evidence regarding the 
integrated roles of renal sodium handling and ARN-mediated sympathetic tone 
in the pathophysiology of age-dependent hypertension in male SD rats. As such, 
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it helps to significantly generate mechanistic insight into the development of age-
dependent hypertension. Additionally, this study is clinically relevant to the 
global epidemic of hypertension, as it is not only models the growing risk of 
developing hypertension with age, but also models the global trend towards 
excess dietary salt intake, which as previously mentioned, drastically increases 
the risk of developing SSH (M. H. Weinberger and Fineberg 1991). 
 Future studies surrounding the mechanisms of age-dependent 
hypertension should look to further define mechanistic targets in the treatment 
of the condition, as such targets may prove useful in the use of CRISPR/cas9 
technology for genetic manipulation. Future studies may also target alternative 
animal models; however, for such experimental approaches to come into fruition, 
established models of hypertension, as well as surgical techniques such as the 
renal pelvic cannulation performed in this present study, need to be developed 
first in animals beyond rats alone. In the clinical setting, blood pressure and NE 
levels are already reliably measured. However, further translating the findings 
and suggestions of this present study into the clinical setting requires more 
definitive considerations surrounding the nature of salt intake in patients and 
novel markers of NCC activity beyond phosphorylation alone. 
Currently, the vast majority of anti-hypertensive treatments available have 
proven to be less effective than expected, especially for the elderly population 
(Imprialos et al. 2016). This is due, among many other possible reasons, 
primarily to risks of increased adverse effects as well as to comorbidities and 
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other complications that arise from aging, and in the case of SSH, a lack of 
routine diagnosis of salt-sensitivity in the elderly human population (Myron H. 
Weinberger 1996). Thus, making significant progress in the treatment of age-
dependent hypertension requires a paradigm shift from a non-specific reduction 
of blood pressure to a mechanistic and personalized approach that targets the 
pathophysiological cause of the hypertension itself. Overall, through the 
demonstration of a hypertensive mechanism, involving an impairment of fluid 
and electrolyte homeostasis that implicates the renal, cardiovascular, and 
nervous systems, this study provides a crucial stepping stone for the development 
of the mechanistic treatment of hypertension in elderly individuals with elevated 
sympathetic tone.  
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